NXP Receives CFIUS Approval for Divestiture of Standard

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NXP Receives CFIUS Approval for Divestiture of Standard Products Business

EINDHOVEN, The Netherlands, Oct. 17, 2016 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ:NXPI) today announced that the Committee on Foreign Investment in the United States (CFIUS) has approved the transaction under which NXP divests its Standard Products business (“Nexperia”) to a consortium of financial investors consisting of Beijing Jianguang Asset Management Co., Ltd (“JAC Capital”) and Wise Road Capital LTD (“Wise Road Capital”).

NXP continues to expect to close the transaction in the first quarter of 2017.

About NXP Semiconductors
NXP Semiconductors N.V. (NASDAQ:NXPI) enables secure connections and infrastructure for a smarter world, advancing solutions that make lives easier, better and safer. As the world leader in secure connectivity solutions for embedded applications, NXP is driving innovation in the secure connected vehicle, end-to-end security & privacy and smart connected solutions markets. Built on more than 60 years of combined experience and expertise, the company has 44,000 employees in more than 35 countries and posted revenue of $6.1 billion in 2015. Find out more at www.nxp.com.

About Beijing Jianguang Asset Management Co., Ltd. (JAC Capital)
Beijing Jianguang Asset Management Co., Ltd. (“JAC Capital”) is a subsidiary of JIC Capital which is part of JIC Group (China Jianyin Investment Ltd). JAC Capital was established for the purpose of investing in the high tech industry including semiconductor, information technology, networking, data service, cloud computing and telecommunications. By taking advantage of the abundant resources of its shareholders in the international financial market, JAC Capital partners with industrial leaders in various sectors and makes investments in the focused high tech industry and the global semiconductors market to support its continuous development. 

About Wise Road Capital LTD (Wise Road Capital)
Wise Road Capital is a global private equity fund that is focused on investing into solid high tech companies by identifying opportunities in enabling technologies for global urbanization and smart/green life through close cooperation with leading companies along several main themes, including smart city, intelligent manufacturing, renewable energies, etc. Wise Road Capital is striving to build a healthy international eco-system around those key themes through its investments and its international management team with a combination of industry and investment background.

Forward-looking Statements
This document includes forward-looking statements which include statements regarding NXP’s business strategy, financial condition, results of operations, and market data, as well as any other statements which are not historical facts. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These factors, risks and uncertainties include the following: market demand and semiconductor industry conditions; the ability to successfully introduce new technologies and products; the end-market demand for the goods into which NXP’s products are incorporated; the ability to generate sufficient cash, raise sufficient capital or refinance corporate debt at or before maturity; the ability to meet the combination of corporate debt service, research and development and capital investment requirements; the ability to accurately estimate demand and match manufacturing production capacity accordingly or obtain supplies from third-party producers; the access to production capacity from third-party outsourcing partners; any events that might affect third-party business partners or NXP’s relationship with them; the ability to secure adequate and timely supply of equipment and materials from suppliers; the ability to avoid operational problems and product defects and, if such issues were to arise, to correct them quickly; the ability to form strategic partnerships and joint ventures and to successfully cooperate with alliance partners; the ability to win competitive bid selection processes to develop products for use in customers’ equipment and products; the ability to successfully establish a brand identity; the ability to successfully hire and retain key management and senior product architects; and, the ability to maintain good relationships with our suppliers. In addition, this document contains information concerning the semiconductor industry and NXP’s business segments generally, which is forward-looking in nature and is based on a variety of assumptions regarding the ways in which the semiconductor industry, NXP’s market segments and product areas may develop. NXP has based these assumptions on information currently available, if any one or more of these assumptions turn out to be incorrect, actual market results may differ from those predicted. While NXP does not know what impact any such differences may have on its business, if there are such differences, its future results of operations and its financial condition could be materially adversely affected. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak to results only as of the date the statements were made. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, NXP does not have any intention or obligation to publicly update or revise any forward-looking statements after we distribute this document, whether to reflect any future events or circumstances or otherwise. For a discussion of potential risks and uncertainties, please refer to the risk factors listed in our SEC filings. Copies of our SEC filings are available on our Investor Relations website, www.nxp.com/investor or from the SEC website, www.sec.gov.

For further information, please contact: Investors: Jeff Palmer jeff.palmer@nxp.com +1 408 518 5411 Media: Joon Knapen joon.knapen@nxp.com +49 151 257 43 299

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Nvidia's Major $500 Million Investment in Wayve for AI Expansion

Updated Category News Views 206

Nvidia Invests $500 Million in Wayve Nvidia, known for its advanced AI technologies, is in discussions to invest a substantial $500 million into the U.K.-based autonomous driving startup Wayve. This move marks a significant step for Nvidia as it seeks to deepen its involvement in the rapidly evolving artificial intelligence sector. Strategic Importance of the Investment...

Continue Reading
Vortex Companies Enhances Leadership with Key Promotions

Updated Category News Views 164

Elevating Leadership at Vortex Companies Vortex Companies, known for its rapid growth in the trenchless infrastructure rehabilitation sector, has recently made significant leadership changes with the promotions of Jonathan Thomas and Connor Mathis. Thomas steps into the role of Senior Regional Vice President for the Coastal Region, while Mathis ascends to Regional Vice...

Continue Reading
Scilex Holding Company Receives FDA Acknowledgment for ELYXYB

Updated Category News Views 118

Scilex Holding Company’s FDA Milestone with ELYXYB Scilex Holding Company, based in Palo Alto, California, has gained significant recognition with the U.S. FDA's acknowledgment of their Supplemental New Drug Application (SNDA) for ELYXYB. This marks a substantial step forward for the company, which is dedicated to creating and advancing non-opioid pain management...

Continue Reading
Bio-Techne Expands AI-Driven Protein Portfolio

Updated Category News Views 8

Advanced Proteins in the Spotlight Bio-Techne’s latest move is creating some serious buzz in the life sciences scene. They're not just talking the talk but walking the walk by expanding their R&D Systems AI-Engineered Designer Protein portfolio. What's the big news? They've engineered heat-stable and hyperactive proteins that promise to shake up fibroblast growth factor...

Continue Reading
PolyPid's D-PLEX100 Trial Results Revolutionize Infection Prevention

Updated Category News Views 146

Groundbreaking Advances in Surgical Infection Prevention PolyPid Ltd. has made headlines recently, unveiling remarkable topline results from their pivotal SHIELD II Phase 3 trial. This innovative study showcased D-PLEX100, a major breakthrough in preventing surgical site infections (SSIs), showing statistically significant reductions in both primary and secondary...

Continue Reading